Clinical Trial Update: A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of a triple therapy with obinutuzumab, ibrutinib, and venetoclax in Richter's Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Syndrome

Drugs mentioned

• Ibrutinib (Imbruvica) (Ibrutinib)
• Obinutuzumab (Gazyva) (obinutuzumab)
• Venetoclax (Venclexta) (venetoclax)

Snippet

Sponsor: Bnai Zion Medical Center | Conditions: Richter's Syndrome | Phase 2 | Status: COMPLETED